Sarepta Therapeutics Receives Buy Rating from Gil Blum: Strategic Partnerships and Financial Stability Highlight Growth Potential
Gil Blum, an analyst from Needham, reiterated the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target was ...
RBC Capital Sticks to Its Buy Rating for American Tower (AMT)
RBC Capital analyst Jonathan Atkin maintained a Buy rating on American Tower (AMT – Research Report) yesterday and set a price target of ...